Saxenda Dose: UK Schedule and Adjustments

Saxenda dose management is a key part of achieving safe and effective weight loss with liraglutide 3 mg. Saxenda follows a structured five-week titration schedule, starting at 0.6 mg once daily and increasing gradually to the 3 mg maintenance dose. This stepwise approach helps the body adjust to the medication and reduces the risk of gastrointestinal side effects. Understanding how the dosing schedule works, when adjustments may be needed, and what side effects to expect at each stage can help you get the most from treatment while staying safe.

How does the Saxenda dosing schedule work in the UK?

Saxenda starts at 0.6 mg once daily and increases weekly over five weeks to the 3 mg maintenance dose, with gradual escalation designed to reduce gastrointestinal side effects. It is a prescription-only medicine requiring clinical assessment before initiation.

Saxenda (liraglutide 3 mg) follows a structured, stepwise dosing schedule in the UK, beginning at a low dose and increasing gradually over five weeks to reach the full therapeutic dose of 3 mg once daily.^[1][2] This escalation approach is designed to allow the body to adjust to the medication and to reduce the likelihood of gastrointestinal side effects such as nausea and vomiting, which are most common when treatment begins.

Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the action of the naturally occurring hormone GLP-1, which helps regulate appetite, slows gastric emptying, and promotes a feeling of fullness after eating. These combined effects support reduced calorie intake and, over time, weight loss.

In the UK, Saxenda is MHRA-authorised as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity (SmPC section 4.1). Saxenda is a prescription-only medicine (POM) and must be prescribed by a qualified prescriber following a clinical assessment. It is administered as a once-daily subcutaneous injection using a pre-filled pen device.

For those considering a structured weight-management consultation, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of treatment options, including Saxenda where clinically appropriate, may be considered. Adherence to the prescribed schedule is important: skipping dose increases or rushing through them without medical guidance can affect both tolerability and effectiveness.

Saxenda Dose Adjustments: When and Why Your Doctor May Change It

Your prescriber may delay a dose increase if side effects are severe, or discontinue treatment if less than 5% body weight is lost after 12 weeks at 3 mg, in line with NICE TA664. Never adjust your dose independently.

Your doctor may adjust your Saxenda dose if you are experiencing persistent side effects, failing to tolerate a scheduled increase, or not achieving the expected clinical response after reaching the maintenance dose. Dose adjustments are a normal and expected part of treatment management, not a sign that the medication is failing.

If side effects such as nausea, vomiting, or diarrhoea are severe or prolonged at a given dose level, your prescriber may advise staying at the current dose for an additional week before attempting the next increase.^[1][2] This extended titration approach is supported by the UK SmPC (section 4.2). Conversely, if a dose level is well tolerated, the schedule should still follow the standard stepwise plan rather than being accelerated, as the gradual increase exists for clinical reasons.

After 12 weeks at the full 3 mg maintenance dose, your prescriber will typically review your progress. According to NICE technology appraisal guidance TA664, treatment should only be continued if you have lost at least 5% of your initial body weight. If this threshold has not been met, your doctor will discuss whether continuing Saxenda is appropriate for you. This review point is an important safety and efficacy checkpoint built into the treatment pathway.

Dose adjustments should always be made in consultation with your prescriber. You should not independently reduce or increase your dose. If you experience a serious adverse effect, such as severe abdominal pain that may indicate pancreatitis, stop using Saxenda immediately and seek urgent medical attention rather than waiting for a routine appointment. For other concerns about how your treatment is progressing, contact your GP or the prescribing service that initiated your treatment.

What side effects should I watch for at each dose level?

Nausea, vomiting and diarrhoea are most common during early escalation at 0.6 mg and 1.2 mg, and usually settle within one to two weeks. Rare but serious risks include pancreatitis and gallbladder disease, both requiring immediate medical attention.

Gastrointestinal side effects are the most commonly reported adverse effects with Saxenda and tend to be most pronounced during the early dose escalation phase, particularly at the 0.6 mg and 1.2 mg dose levels. These include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. For most people, these effects are mild to moderate and improve as the body adjusts over one to two weeks at each dose level (SmPC section 4.8).

As the dose increases towards 1.8 mg, 2.4 mg, and ultimately 3 mg, some individuals may notice that side effects return briefly before settling again. Staying well hydrated and eating smaller, lower-fat meals can help manage nausea during these transitions. If vomiting or diarrhoea is severe or persistent, there is a risk of dehydration and, in some cases, acute kidney injury. You should maintain adequate fluid intake throughout treatment. If you notice signs of dehydration such as dizziness, reduced urination, or persistent vomiting or diarrhoea, contact your GP or call NHS 111 for advice.

Less commonly, Saxenda has been associated with an increased heart rate and injection site reactions such as redness or bruising. Saxenda is not recommended in people with severe gastrointestinal disease, including gastroparesis, as it slows gastric emptying and may worsen these conditions; discuss your full medical history with your prescriber before starting treatment (SmPC section 4.^[1][2]4).

Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been reported with liraglutide.^[1][13] If you develop symptoms such as pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice), stop using Saxenda and seek prompt medical attention.

Rarely, acute pancreatitis has been reported with Saxenda, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome (SmPC section 4.4). If you develop severe and persistent abdominal pain, particularly pain that radiates to the back, stop using Saxenda and seek urgent medical attention by calling 999 or going to your nearest A&E department.

If you have type 2 diabetes and are also taking insulin or a sulfonylurea alongside Saxenda, you may be at increased risk of hypoglycaemia (low blood sugar). Your prescriber may need to reduce the dose of your insulin or sulfonylurea when starting Saxenda; do not adjust these doses yourself without medical advice.

Saxenda should not be used at the same time as another GLP-1 receptor agonist (for example, semaglutide or dulaglutide), as the combination has not been studied and may increase the risk of adverse effects.

Saxenda must not be used during pregnancy. If you become pregnant while taking Saxenda, stop treatment and contact your prescriber promptly. You should also discuss the use of Saxenda with your prescriber if you are planning a pregnancy or breastfeeding, as it is generally not recommended during breastfeeding.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps build the national evidence base for medicine safety. Always read the patient information leaflet supplied with your medication and discuss any concerns with your prescriber or pharmacist.

What is the starting dose and how does it increase over time?

The starting dose is 0.6 mg once daily for the first week, used solely to improve tolerability, before weekly increases to the 3 mg maintenance dose from week five onwards. If more than three consecutive doses are missed, contact your prescriber before restarting.

The starting dose of Saxenda is 0.6 mg once daily, administered by subcutaneous injection, and this initial dose is maintained for the first week of treatment. The 0.6 mg dose is not a therapeutic dose for weight management; its purpose is solely to improve tolerability before the dose is escalated (SmPC section 4.2).

After the first week, the dose increases in weekly steps as follows:

• Week 1: 0.6 mg once daily

• Week 2: 1.2 mg once daily

• Week 3: 1.8 mg once daily

• Week 4: 2.4 mg once daily

• Week 5 onwards: 3.0 mg once daily (maintenance dose)

The 3 mg once-daily dose is the recommended maintenance dose for chronic weight management and should be continued long term, provided treatment is effective and well tolerated. There is no dose above 3 mg; this is the maximum authorised dose for Saxenda in the UK.

Saxenda can be injected at any time of day, with or without food, but it is advisable to choose a consistent time each day to support adherence. The injection is given under the skin of the abdomen, thigh, or upper arm, and the injection site should be rotated regularly to avoid localised skin reactions. Saxenda pens and needles must never be shared with another person, even if the needle has been changed, due to the risk of infection.^[1][11]

If you miss a dose, inject it as soon as you remember, provided your next scheduled dose is at least 12 hours away. If fewer than 12 hours remain until your next dose, skip the missed dose and resume your usual schedule. Never inject two doses to make up for a missed one. If you miss more than three consecutive days of treatment, contact your prescriber before restarting, as re-titration from 0.6 mg may be recommended (PIL, How to use Saxenda).

Scientific References

1. Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
2. Saxenda, INN-liraglutide – EPAR Product Information.
3. Saxenda – European Medicines Agency medicine page.
4. Liraglutide for managing overweight and obesity. Technology Appraisal Guidance TA664.
5. Liraglutide for managing overweight and obesity – TA664 Chapter 2: Information about liraglutide.
6. Liraglutide for managing overweight and obesity – TA664 supporting document.
7. Liraglutide – British National Formulary (BNF).
8. Liraglutide: a medicine to treat type 2 diabetes or obesity.
9. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
10. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
11. Saxenda 6 mg/mL solution for injection – Patient Information Leaflet (PIL).
12. Liraglutide-induced acute kidney injury.
13. Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes. United European Gastroenterology Journal.
14. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study. Pharmacotherapy.
15. Association of incretin-based therapies with hepatobiliary disorders among patients with type 2 diabetes: a case series from the FDA adverse event reporting system. Endocrine Connections.

Frequently Asked Questions